Geode Capital Management
KYMR icon

Geode Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Geode Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$208M Buy
1,816,331
+170,981
+10% +$14.7M 0.01% 781
2026
Q1 		$137M Buy
1,645,350
+227,961
+16% +$18.1M 0.01% 900
2025
Q4 		$110M Buy
1,417,389
+140,623
+11% +$9.5M 0.01% 1011
2025
Q3 		$72.3M Buy
1,276,766
+83,654
+7% +$3.77M ﹤0.01% 1260
2025
Q2 		$52.1M Buy
1,193,112
+59,347
+5% +$2.04M ﹤0.01% 1400
2025
Q1 		$31M Buy
1,133,765
+28,278
+3% +$1.03M ﹤0.01% 1654
2024
Q4 		$44.5M Buy
1,105,487
+52,263
+5% +$2.36M ﹤0.01% 1499
2024
Q3 		$49.9M Sell
1,053,224
-996
-0.1% -$44K ﹤0.01% 1428
2024
Q2 		$31.5M Buy
1,054,220
+88,520
+9% +$3.06M ﹤0.01% 1666
2024
Q1 		$38.8M Buy
965,700
+85,185
+10% +$3.05M ﹤0.01% 1518
2023
Q4 		$22.4M Buy
880,515
+46,288
+6% +$828K ﹤0.01% 1838
2023
Q3 		$11.6M Buy
834,227
+32,942
+4% +$662K ﹤0.01% 2170
2023
Q2 		$18.4M Buy
801,285
+20,456
+3% +$586K ﹤0.01% 1898
2023
Q1 		$23.1M Buy
780,829
+33,758
+5% +$1.09M ﹤0.01% 1694
2022
Q4 		$18.6M Buy
747,071
+45,849
+7% +$1.22M ﹤0.01% 1817
2022
Q3 		$15.3M Buy
701,222
+25,375
+4% +$669K ﹤0.01% 1935
2022
Q2 		$13.3M Buy
675,847
+52,077
+8% +$1.22M ﹤0.01% 2048
2022
Q1 		$26.4M Buy
623,770
+3,728
+0.6% +$157K ﹤0.01% 1699
2021
Q4 		$39.4M Buy
620,042
+20,172
+3% +$1.17M ﹤0.01% 1483
2021
Q3 		$35.2M Buy
599,870
+258,328
+76% +$15M ﹤0.01% 1569
2021
Q2 		$16.6M Buy
341,542
+154,884
+83% +$6.72M ﹤0.01% 2100
2021
Q1 		$7.25M Sell
186,658
-5,263
-3% -$317K ﹤0.01% 2582
2020
Q4 		$11.9M Buy
191,921
+155,727
+430% +$7.6M ﹤0.01% 2046
2020
Q3 		$1.17M Buy
+36,194
New +$1.1M ﹤0.01% 3148

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Geode Capital Management's KYMR Position: Q2 2026 in Review

Geode Capital Management increased its Kymera Therapeutics (KYMR) stake by 10% in Q2 2026, buying an estimated $14.7M and bringing the position to 1,816,331 shares worth $208M. The position accounts for 0.01% of the portfolio, ranked #781.

Geode Capital Management first reported a position in KYMR in Q3 2020 and has held it in 24 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Geode Capital Management held 1,816,331 shares of Kymera Therapeutics worth $208M as of Q2 2026.
  • Geode Capital Management bought 170,981 Kymera Therapeutics shares in Q2 2026, an estimated $14.7M.
  • Kymera Therapeutics made up 0.01% of Geode Capital Management's portfolio in Q2 2026, its #781 holding.
  • Geode Capital Management first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.